Skip to main content
. 2017 Nov 23;34(11):859–868. doi: 10.1007/s40266-017-0498-y
Elderly patients with IBD have an increased risk of malignancy when compared with the general population.
This increased risk was associated with corticosteroid use, but not with immunomodulators or biologics.
The elderly are more likely to be treated with corticosteroids than corticosteroid-sparing agents.